BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36537905)

  • 21. Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update.
    Petrou P
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(6):625-650. PubMed ID: 37288738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.
    Maziarz RT; Yang H; Liu Q; Wang T; Zhao J; Lim S; Lee S; Dalal A; Bollu V
    Leuk Lymphoma; 2022 Sep; 63(9):2052-2062. PubMed ID: 35422192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Manufacturing Procedures on CAR T Cell Functionality.
    Watanabe N; Mo F; McKenna MK
    Front Immunol; 2022; 13():876339. PubMed ID: 35493513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
    Yang J; Zhou W; Li D; Niu T; Wang W
    Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas.
    Riedell PA; Hwang WT; Nastoupil LJ; Pennisi M; McGuirk JP; Maziarz RT; Bachanova V; Oluwole OO; Brower J; Flores OA; Ahmed N; Schachter L; Bharucha K; Dholaria BR; Schuster SJ; Perales MA; Bishop MR; Porter DL
    Transplant Cell Ther; 2022 Oct; 28(10):669-676. PubMed ID: 35850429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
    Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
    Front Immunol; 2021; 12():693200. PubMed ID: 34290712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second-Line Chimeric Antigen Receptor T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A Cost-Effectiveness Analysis.
    Kelkar AH; Cliff ERS; Jacobson CA; Abel GA; Dijk SW; Krijkamp EM; Redd R; Zurko JC; Hamadani M; Hunink MGM; Cutler C
    Ann Intern Med; 2023 Dec; 176(12):1625-1637. PubMed ID: 38048587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sequence not salvage.
    Sborov DW; Fortuna GG; Hayden PJ
    Br J Haematol; 2024 May; 204(5):1590-1592. PubMed ID: 38563345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
    Ghilardi G; Paruzzo L; Patel V; Svoboda J; Chong ER; Fardella E; Chong EA; Gabrielli G; Nasta SD; Landsburg DJ; Carter J; Pajarillo R; Barta SK; White G; Weber E; Napier E; Porter DL; Garfall AL; Schuster SJ; Ruella M
    J Hematol Oncol; 2024 Apr; 17(1):19. PubMed ID: 38644469
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
    Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma.
    Strassl I; Podar K
    Expert Opin Drug Discov; 2024 Apr; 19(4):377-391. PubMed ID: 38369760
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US.
    Ghanem B; Shi L
    BioDrugs; 2022 Nov; 36(6):773-780. PubMed ID: 36167952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
    Halford Z; Anderson MK; Bennett LL
    Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.
    Maloney DG; Kuruvilla J; Liu FF; Kostic A; Kim Y; Bonner A; Zhang Y; Fox CP; Cartron G
    J Hematol Oncol; 2021 Sep; 14(1):140. PubMed ID: 34493319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel CAR T cell therapies for patients with large B cell lymphoma.
    Goto H; Onozawa M; Teshima T
    Int J Hematol; 2024 May; ():. PubMed ID: 38795249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States.
    Liu R; Oluwole OO; Diakite I; Botteman MF; Snider JT; Locke FL
    J Med Econ; 2021; 24(1):458-468. PubMed ID: 33691581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.
    Tsutsué S; Makita S; Asou H; Matsuda H; Yamaura R; Taylor TD
    Future Oncol; 2024 Apr; ():1-17. PubMed ID: 38597742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lisocabtagene maraleucel for relapsed or refractory large B-cell non-Hodgkin lymphoma.
    Mohty R; Moreno Vanegas Y; Chavez JC; Kharfan-Dabaja MA
    Expert Rev Anticancer Ther; 2023 Feb; 23(2):121-126. PubMed ID: 36662602
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Droplet digital PCR allows vector copy number assessment and monitoring of experimental CAR T cells in murine xenograft models or approved CD19 CAR T cell-treated patients.
    Haderbache R; Warda W; Hervouet E; da Rocha MN; Trad R; Allain V; Nicod C; Thieblemeont C; Boissel N; Varlet P; Agha IY; Bouquet L; Guiot M; Venet F; Sujobert P; Roussel X; Rouzaire PO; Caillot D; Casasnovas O; Bories JC; Bachy E; Caillat-Zucman S; Deschamps M; Ferrand C
    J Transl Med; 2021 Jun; 19(1):265. PubMed ID: 34154602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.